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INTRODUCTION 
 
Stroke is the most common neurological disorder worldwide and it is the most 
frequent of all the neurological disorders. Stroke is also known Cerebrovascular 
Accident (CVA), derived from Greek word in the year 1599 which means ‘Struck 
Down’
1
. It is the disease of developed nations. 
 
According to the World Health Organization, 15 million people suffer from stroke 
worldwide every year. Of these, 5 million die and another 5 million are 
permanently disabled
2
. 
The incidence of stroke is higher in men than in women. Every year there are about 
approximately 700,000 cases of stroke, roughly 600,000 ischemic lesions and 
100,000 hemorrhages, with 175,000 fatalities from these causes.
3
 
It is estimated that by the year 2020 stroke will become the 4
th
 leading cause of 
disability adjusted life years.
4
 The prevalence of stroke in India is estimated to be 
203/100000 population above 20 years of age. The disability and morbidity is 
higher in elderly with doubling of death due to stroke in United States by the year 
2030.
5
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Cerebrovascular Accident is defined as the abrupt onset of focal neurological 
deficit. It was described as if the patient was struck by the hand of God. Stroke 
may be due to ischemia or hemorrhage, 87% of the stroke are ischemic. 
Occurrence of stroke leads to a lot of physical disability and also cognitive and 
behavioral impairment. The most important risk factors that contribute to stroke 
are Systemic hypertension, Diabetes mellitus, dyslipidemia, Cigarette smoking and 
heart diseases. These risk factors causing stroke when modified and kept under 
strict control have substantial influence in preventing its occurrence and reducing 
its severity. 
The platelets play a major role in pathogenesis of vascular disease. Platelet size 
and function is measured by Mean Platelet Volume (MPV). Platelet activity is 
accentuated in acute ischemic stroke due to blood vessel occlusion that leads to 
ischemia, endothelial damage and new platelet formation. The new younger 
platelets are larger in size due to increase in α granules and the presence of platelet 
factor 4. Thus the mean platelet volume is elevated in ischemic stroke. Studies 
conducted worldwide, have found that mean platelet volume has prognostic 
significance in determining the outcome and severity of stroke. Similar studies 
have not been conducted much in our country. In this study the prognostic 
significance of Mean platelet volume has been assessed and its significance 
evaluated. 
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AIMS AND OBJECTIVES 
 
• PRIMARY OBJECTIVE: 
Analyze the Mean Platelet Volume in patients who have suffered an 
ischemic stroke when compared to a control population.  
 
• SECONDARY OBJECTIVE(S): 
a. Analyze the association between Mean Platelet Volume and severity 
of ischemic stroke (which can be based on modified Rankin’s scale at 
1 week after ischemic stroke and on outcome at 1 month) 
b. Analyze the effect of comorbid illnesses (such as Diabetes, 
Hypertension, Dyslipidemia) on Mean Platelet Volume in ischemic 
stroke patients. 
c. Analyze the effect of drugs (such as Aspirin, Clopidogrel, Statins, 
ACE inhibitors, Anticoagulants[in AF with stroke]) by comparing 
Mean Platelet Volume values at admission and after 1 month during 
which period the patient may have been started on any of the above 
medications. 
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REVIEW OF LITERATURE 
 
Stroke is the most common neurological disorder worldwide and it is the most 
frequent of all the neurological disorders. 
About 2,400 years ago in the year400 BC the father of medicine, Hippocrates 
described stroke as sudden onset of paralysis and coined the term Apoplexy, a 
general term used by physicians which means struck down with violence
6
. As there 
were numerous conditions that lead to sudden paralysis, the term apoplexy did not 
indicate a specific diagnosis. 
Followed by Hippocrates, Johann Jacob Wepfer was the one who investigated the 
pathological signs of apoplexy. He was the first to identify the postmortem signs of 
bleeding in the brains of patient who died of apoplexy. From autopsy study he 
gained the knowledge of carotid and vertebral arteries supplying blood to the brain. 
He suggested that the blockage of the main arteries can also lead to apoplexy in 
addition. Thus in the year 1928 apoplexy was categorized depending on the blood 
vessel pathology which lead to the term Stroke or Cerebrovascular disease 
(“cerebro” means part of the brain, vascular refers to blood vessels)
7 
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In humans, the moment the blood vessel gets occluded the brain damage begins 
and continues for days afterwards. So there is a very short window period for the 
treatment of most common forms of stroke. Because of this the significance of 
prevention is to be highlighted and primary preventive strategies need to be 
identified.  
 
PREVALANCE OF STROKE 
Stroke is the disease of developed and the rich nations. The incidence of stroke is 
higher in men than in women. It is more common in the elderly but can occur at 
any age. Every year there are about approximately 700,000 cases of stroke, roughly 
600,000 ischemic lesions and 100,000 hemorrhages, with 175,000 fatalities from 
these causes. 
It is estimated that by the year 2020 stroke will become the 4
th
 leading cause of 
disability adjusted life years (DALY). 
Stroke is defined as a sudden occurrence of a non conclusive, focal neurological 
deficit, described as if the patient has been struck by the hand of God. 
Stroke may be due to ischemia or hemorrhage. 87% of all stroke are ischemic.
8 
  
6 
 
RISK FACTORS  
 The most important risk factor that ranks first in association with stroke is 
Systemic Hypertension. It has been proved that the control of blood pressure 
will decrease the risk of occurrence of stroke in an individual. 
 The other risk factors are 
o Diabetes. 
o  Hyperlipidemia. 
o Smoking – Increase the rate of Carotid atherosclerosis 
o Atrial fibrillation – mainly due to cardiac cause. 
o Infective endocarditis (Bacterial and Non bacterial) leading on to 
embolic stroke. 
o Right to left shunts 
o Systemic – Hypercoagulable conditions like APLA. 
o Usage of Oral Contraceptive Pills. 
o Symptomatic Carotid Artery Stenosis-70-99% of patients develop 
stroke. 
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ISCHEMIC STROKE 
Ischemic Stroke refers to occurrence of stroke due to decreased cerebral perfusion 
due to thrombosis or embolism. 
ETIOLOGY: 
The following table enlists the common and uncommon causes. 
Common Causes Uncommon Causes 
Thrombosis Hypercoagulable disorders 
Lacunar stroke (small vessel) Protein C deficiency 
Large vessel thrombosis Protein S deficiency 
Dehydration Antithrombin III deficiency 
Embolic occlusion Antiphospholipid syndrome 
Artery-to-artery Factor V Leiden mutationa 
Carotid bifurcation Prothrombin G20210 mutation 
Aortic arch Systemic malignancy 
Arterial dissection Sickle cell anemia 
Cardioembolic Thalassemia 
Atrial fibrillation Polycythemia vera 
Mural thrombus Systemic lupus erythematosus 
Myocardial infarction Homocysteinemia 
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Dilated cardiomyopathy Thrombotic thrombocytopenic purpura 
Valvular lesions Disseminated intravascular coagulation 
Mitral stenosis Dysproteinemias 
Mechanical valve Nephrotic syndrome 
Bacterial endocarditis Inflammatory bowel disease 
Paradoxical embolus Oral contraceptives 
Atrial septal defect Venous sinus thrombosisb 
Patent foramen ovale Fibromuscular dysplasia / Vasculitis 
Atrial septal aneurysm Primary CNS vasculitis 
Spontaneous echo contrast Systemic vasculitis 
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Few rare causes of ischemic stroke includes: 
Hypercoagulable disorders:  
A variety of disorders are associated with increased risk of thrombosis. Protein C 
and S deficiency cause arterial thrombosis. SLE, Limbman Sacs endocarditis 
causes embolic stroke. Sickle cell anemia is a common cause of stroke in children. 
 
Fibromuscular Dysplasia: 
Fibromuscular Dysplasia affects the vertebral arteries commonly and is more 
common in women. Usually an incomplete occlusion occurs. Renal artery 
involvement is common and may cause hypertension. Usually asymptomatic but 
may be associated with audible bruit, Stroke. 
Temporal (Giant Cell) Arteritis: 
Temporal (Giant Cell) arteritis is common in old age. Temporal arteries undergoes  
gramulomatous inflammation with giant cells. 
Takayasu Arteritis:  
Takayasu arteritis or idiopathic giant cell arteries involves the great vessels like 
aortic arch, carotid or vertebral artery leading to thrombosis. 
10 
 
Moya Moya Disease: 
Moya Moya disease involves the large arteries commonly. The occlusion occurs at 
the stem of Middle Cerebral Artery and Anterior Cerebral Artery. The presense of 
collateral circulation gives the appearance of puff of smoke. 
Reversible Posterior Leukoencephalopathy: 
There is an extensive cerebral segmental vasoconstriction leading to cerebral 
ischemia. The pathophysiology is uncertain but the ischemia is reversible 
completely. 
Leukoaraiosis: 
Leukoaraiosis or Periventricular white matter disease causes multiple small vessel 
infarcts within the subcortical white matter. It is due to lipohyalinolysis of small 
penetrating arteries. It commonly occurs in chronic SHT. 
CADASIL (Cerebral autosomal dominant arteriopathy with subcortical infarcts 
and leucoencephalopathy) most commonly presents as small vessel stroke. 
TRANSIENT ISCHEMIC ATTACK (TIA): 
If the neurological sign and symptoms resolve within 1 day (24 hours), irrespective 
of imaging evidence of new brain changes , it’s termed as Transient 
IschemicAttack.
10
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One third of TIA occurs in patients with hypertension. They are preceded or 
followed by stroke. In 20% of TIA stroke occurs within one month and in 50% 
within one year.
11
 TIA is the warning sign of an impending blood vessel 
occlusion.TIA of longer duration ,multiple episodes each with different pattern is 
most probably due to embolism, whereas recurrent brief attacks with similar 
pattern are mostly due to atherosclerosis and thrombosis. 
TIA can also occur due to increased viscosity of the blood, as in hypercoagulable 
states, polycythemia vera, Leukemia. It occurs most commonly in vertebro basilar 
system rather than in the carotid system.
13
 The risk of occurrence of myocardial 
infarction is high after transient ischemic attack. 
PATHOPHYSIOLOGY OF ISCHEMIC STROKE: 
The pathophysiology of occurrence of ischemic stroke depends on its etiology and 
risk factors. The pathology may be either due to thrombus or embolism or 
decreased perfusion due to stenosis in arterial system causing occlusion. 
o Altered permeability of vessel wall 
o Change in the viscosity mainly increased viscosity of the blood 
o Blood vessel rupture 
o Atherosclerosis 
12 
 
o Aneusymal dilatation 
o Hypertension 
o  Atheroscelerosis. 
o Arteritis and vasospasm 
o Developmental malfunction. 
 
It is difficult to distinguish the lesion of an embolism or thrombosis. Embolic 
stroke occurs suddenly and the neurological deficit is to the maximum at the onset. 
Thrombotic stroke occurs less abruptly and takes longer time for the stroke to 
evolve. Thrombosis of vessels may lead to artery to artery embolism. The stenosis 
occurs most commonly due to atherosclerosis and plaque deposition. 
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Stenosis, Embolism and Thrombosis are shown in this diagram. 
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The extent of ischemia depends on degree and duration of occlusion and also the 
presence or absence of other associated factors like 
• Blood pressure:  
Systemic blood pressure determines the cerebral perfusion pressure. When 
blood pressure is lowered the cerebral perfusion pressure also decreases 
leading to global cerebral ischemia. 
• Hyperthermia:  
 Ischemic injury is much severe if there is elevated body temperature. 
• Glucose level: 
Both hypoglycemia and hyperglycemia are associated with a poorer 
outcome. 
• Hypercoagulable state: 
If there is an associated hypercoagulable state there is an increase in micro 
thrombi formation and worseninig of blood vessel occlusion. 
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NEURONAL DEATH: 
Neuronal death occurs by two ways: 
• Apoptosis: 
Apoptosis is defined as programmed cell death that occurs in neurons in 
certain conditions like ischemia. The nucleus is damaged first followed by 
activation of suicide proteins in the nuclei, that begins the autolytic process 
resulting in cell death. This process is mediated by DNA cleavage. The 
process of apoptosis takes only 1 hour.
12
 
• Coagulation Necrosis: 
Coagulation necrosis is a process by which cell death occurs without 
inflammation. This is due to damage to the plasma membrane by physical 
and chemical stimuli. The cell initially swells then shrinks. This process 
takes 6-12 hours to evolve. By 24 hours there is complete necrosis.
13
 
The morphology of cell death in apoptosis is different from cell death due to 
coagulation necrosis.
14
 
• Thrombosis: 
Atherosclerosis is the most common pathological cause for the occlusion of 
blood vessel that leads to thrombosis.The plaque that is formed may be 
fractured ulcerated or calcified. Damage to the endothelium activates 
16 
 
vasoactive enzymes and release various factors that contribute to thrombosis 
and occlusion
15
. 
The other pathological causes of thrombosis is hypercoagulable state by 
formation of clot, micro thrombi that occurs in conditions like Giant cell 
Arteritis, APLA. 
• Lacunar Infarcts:  
Lacunar Infarct is due to the occlusion of small penetrating arteries arising 
from the cerebral arteries . These may be 100-400 mm in diameter. The size 
of the infarct is about 20mm in diameter. The pathology is due to 
lipohyalinolysis.
16,17
 The incidence is around 10-30% of all strokes. In 
people with chronic hypertension, the small arterioles are tortuous, long and 
forms microaneurysm that makes the arteriole susceptible to occlusion. 
• Embolism: 
Embolisation of artery may be due to various causes and the most common 
cause is Cardiac source. Most of the emboli occludes the middle cerebral 
artery, because 80% of the the blood flow occurs through this artery.
18
 Apart 
from this the superficial branch of cerebral and cerebellar arteries are 
involved though less frequently. The embolic occlusion can also cause 
vasospasm by acting as an irritant to the blood vessel. Vasospasm is the 
17 
 
more frequent in younger than the elder patients, because blood vessels in 
younger individuals are not much atherosclerotic. 
The important determinants of pale or hemorrhagic infarct are  
a. The size of the infarct  
b. The adequacy of the collaterals 
c. The initiation of therapy like anticoagulants and thrombolysis 
Hypertension is not the independent risk factor for hemorrhagic infarct.
19,20
 
• Global Ischemia: 
Global Ischemia is also known as the Hypotensive stroke. Systemic hypotension 
due to any cause can lead to global ischemia. The most commonly affected cells 
are pyramidal cell layer of hippocampus and the purkinje cell layer of cerebral 
cortex. The grey matter in cerebrum is also susceptible to this ischemia. It occurs 
most frequently in the water shed area, that is present at the junction of anterior, 
middle and posterior cerebral arteries. 10% of the infarct are water shed infarcts. It 
occurs due to carotid stenosis in 40%.
21
 
The clinical presentation of water shed infarct is weakness, sensory involvement 
involving the upper limb more than the lower limb, face is usually spared and the 
speech is not affected. 
18 
 
Unlike any other organs, Brain depends entirely on glucose for its metabolism as it 
lacks Glycogen which stores glucose, and brain also lacks the anaerobic 
metabolism. The centres in the lower brain stem regulate the constant blood supply 
to the brain by stimulation of Vasomotor reflexes and Baroreceptors. Decrease in 
blood flow for even 4 to 10 minutes produces a rapid symptom of neurological 
deficit.
22
  
The normal cerebral blood flow is 50-60 ml/100 gm/min.
23
 Below this level there 
is cerebral vasodilatation, the collaterals get opened and the oxygen extraction 
from the other cells increases. When it is less than 20ml/100gm/min, the cerebral 
auto regulatory mechanism gets impaired. The brain tissue goes for infarction over 
an hour, if the blood flow is 16-18ml/100gm/min. And finally irreversible neuronal 
injury occurs if blood flow is less than 10ml/100gm/min.
24
 
Once the infarction had occurred there is increased water accumulation 
immediately both intracellularly and in intercellular spaces leading to swelling of 
the infarcted area. There is a release of inflammatory mediators and leucocyte gets 
recruited .These released mediators cause vasodilation and platelet aggregation. 
The immunoregulated platelets, erythrocytes and leuckocytes gets adhered to the 
vessel wall leading to occlusion and ischemia. 
19 
 
When brain tissue completely is completely deprived of the blood flow leading to 
irreversible neuronal destruction, it’s termed as Global Ischemia. If the collaterals 
are able to maintain the blood flow and oxygen it is known as focal ischemia 
The core region surrounding infarcted area is ischemic. This zone is known as 
ischemic penumbra, which has viable neurons and marginal 
perfusion.
25
Maintaining the blood flow to this ischemic penumbra is the targeted 
factor in ischemic stroke because this ischemia area recovers from injury once the 
flow is re-established but when the flow is not reversed it goes for infarction 
leading to worsening of the clinical status and outcome. Ischemic penumbra is seen 
in MRI / CT – perfusion- diffusion imaging. The newly emerging modalities of 
treatment like Revascularisation therapies are aimed at saving the ischemic 
penumbra to prevent further infarction. 
There are two types of infarct 
o Pale Infarct 
o Hemorrhagic Infarct 
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a) Pale Infarct 
 
b) Hemorraghic Infarct 
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BIOCHEMICAL CHANGES: 
These depolarised cells when injured produces efflux of potassium, depletion of 
ATP and Creatine kinase. Groen et al proposed that low serum potassium increases 
the stroke rate
26
. Accumulation of free fatty acids destroys the phospholipids in cell 
membranes of neurons, which alters the calcium homestasis. These changes lead to 
histological features of necrosis. The increased extracellular potassium and 
intracellular calcium causes cellular acidosis. 
The cells swell due to accumulation of cytokines and other inflammatory mediators 
like prostaglandins leading to cytotoxic edema.
27
 
CHANGES DUE TO ALTERED METABOLIC FACTORS: 
• Glutamate: 
Glutamate is a excitatory neuro transmitter that is cleared by glutamate 
transporters from the extracellular space. Following stroke the glutamate 
transporters release glutamate. Glutamate is excitotoxic, so its release causes 
brain damage following stroke. Glutamate also increases calcium influx 
leading to persistent depolarization and activation of enzymes, release of 
cytokines and loss of cellular integrity. 
 
22 
 
• Mitochondrial Dysfunction: 
Activation of neuronal NOS, inducible nitric oxide in glial cells lead to 
Mitochondrial damage and causes ischemia of the brain. 
 
 
 
23 
 
TYPES OF ISCHEMIC STROKE:  
There are various classification systems for acute ischemic stroke.  
The Oxford Community Stroke Project classification (OCSP, also known as the 
Bamford or Oxford classification) relies primarily on the initial symptoms; based 
on the extent of the symptoms, the stroke episode is classified as- 
a) Total anterior circulation infarct (TACI). 
b) Partial anterior circulation infarct (PACI). 
c) Lacunar infarct (LACI). 
d) Posterior circulation infarct (POCI). 
 These four entities predict the extent of the stroke, the part of the brain affected 
the underlying cause, and the prognosis. 
The TOAST (Trial of Org 10172 in Acute Stroke Treatment) classification is based 
on clinical symptoms as well as results of further investigations; on this basis, a 
stroke is classified as being due to- 
a) Thrombosis or embolism due to atherosclerosis of a large artery. 
b) Embolism of cardiac origin. 
c) Occlusion of a small blood vessel. 
24 
 
d) Other determined causes. 
e) Undetermined cause (two possible causes, no cause identified, or incomplete 
investigation).  
ANTERIOR CIRCULATION STROKE (ACS): 
 The major blood vessels involved in ACS are 
o Carotid Artery mainly internal carotid artery (ICA) 
o Middle cerebral artery (MCA) 
o Anterior cerebral artery 
o Anterior choroidal artery 
 When ACA and MCA are occluded at the top of carotid artery – abulia or 
stupor / occur with aphasia, anasognosia, hemiplegia, hemianisocoria and 
amaurosis fugax. 
Middle Cerebral Artery (MCA): 
MCA involvement causes symptoms of contralateral hemiplegia, homonymous 
hemianopia, hemianaesthesia, gaze preference to same side and Wernicke’s 
aphasia. 
 
25 
 
Anterior cerebral artery (ACA):  
ACA involvement causes bilateral pyramidal signs, profound abulia, paraparesis or 
quadriparesis and urinary incontinence.  
Anterior choroidal artery: 
Anterior choroidal artery involvement leads to contralateral hemiplegia, 
homonymous hemianopia and hemianaesthesia. 
Common carotid artery:  
Common carotid artery involvement causes Jaw claudication. 
POSTERIOR CIRCULATION STROKE (PCS): 
The arteries involved are posterior cerebral artery, posterior inferior cerebellar 
artery, Vertebral Artery, Basilar Artery. Posterior circulation syndromes are 
because of emboli / atheroma formation, at the top of basilar artery.  
P1 Syndrome and P2 Syndrome are due to Posterior cerebral artery occlusion. The 
features are 
• Contralateral homonymous hemianopia with macular sparing. 
• Bilateral infarction of distal PCA  
• Cortical blindness 
26 
 
• Anton’s Syndrome 
• Balint’s syndrome - Balint’s syndrome occurs due to infarction in water shed 
area between MCA and PCA. 
• Embolic occlusion of top of basilar artery - Bilateral signs, ptosis, pupillary 
asymmetry, absence of light reflex and somnolecence. 
• Vertebral and Posterior ICA - Lateral medullary Syndrome, Medial 
medullary Syndrome. 
• Hemiparesis is not the feature of vertebral artery occlusion, but quadriparesis 
can result from occlusion of anterior spinal artery. 
INVESTIGATIONS: 
CT Brain: 
Brain CT scans obtained in the first several hours after an infarction generally 
show no abnormality, and the infarct may not be seen reliably for 24–48 hours. 
MRI: 
MRI reliably documents the extent and location of infarction in all areas of the 
brain, including the posterior fossa and cortical surface 
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Conventional x-ray cerebral angiography: 
Conventional x-ray cerebral angiography is the gold standard for identifying and 
quantifying atherosclerotic stenosis of the cerebral arteries. 
Ultrasound Techniques: 
Stenosis at the origin of the internal carotid artery can be identified and quantified 
reliably by ultrasonography that combines a B-mode ultrasound image with a 
Doppler ultrasound assessment of flow velocity ("duplex" ultrasound). 
Transcranial Doppler (TCD) assessment of MCA, ACA, and PCA flow and of 
vertebrobasilar flow is also useful. This latter technique can detect stenotic lesions 
in the large intracranial arteries because such lesions increase systolic flow 
velocity. Furthermore, TCD can assist thrombolysis and improve large artery 
recanalization following rtPA administration. 
Perfusion Techniques: 
Both xenon techniques (principally xenon-CT) and PET can quantify cerebral 
blood flow. These tools are generally used for research but can be useful for 
determining the significance of arterial stenosis and planning for revascularization 
surgery. Single-photon emission computed tomography (SPECT) and MR 
perfusion techniques report relative cerebral blood flow. 
28 
 
Disability adjusted life year (DALY): 
Disability adjusted life year is used to measure the global burden of disease. It’s 
the healthy time lost by the patient due to early mortality and life with morbidity. 
Modified Rankin’s scale is commonly used in India to evaluate DALY.
28
 
Modified Rankin’s Scale
29
: 
It is one of the commonly used clinical outcome measures in patients with stroke 
0 → No symptoms 
1 → No significant disability, able to carry out all usual activities despite some 
symptoms 
2 → Slight disability, able to look after own affairs without assistance, but unable 
to carry out all the previous activities. 
3 → Moderate disability, requires some help, but able to walk unassisted. 
4 → Moderately severe disability. Unable to attend own bodily needs without 
assistance and unable to walk unassisted. 
5 → Severe disability, requires constant , nursing care and attention, bed ridden 
and incontinent. 
6 → Dead. 
29 
 
PLATELETS: 
 Platelets are small, non nucleated cells with occasional reddish granules 
present in blood vessels. 
 It was first described by Addision in 1841 as extremely minute granules in 
clotting blood
30
. 
 In 1906 it was James Horer Wright who put forth a hypothesis that platelets 
are derived from cytoplasm of Megakaryocytes.
31
 
 Platelets are produced in yolk sac at first goes to liver and then to Bone 
Marrow at the time of gestation 
 The half life of platelets is 7 – 10 days .Platelet production increase > 10 fold 
in stress.
32
 Stress platelets are large, beaded in shape. Recticulated platelets 
are young, released from bone marrow and term reticulated refers to RNA 
content and in analogues to young red cells reticulocytes
33
. 
 1/3rd of platelets are produced in spleen and platelet count is 150000 to 
450000 / µl. 
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The Lentiform Shape of Circulating Platelets: 
 
 
Megakaryopoiesis: 
About 1x10
8  
megakaryocytes are produced in the bone marrow every day. Colony 
forming unit megakaryocytes develops into 3-50 mature megakaryocytes. Burst 
forming unit megakaryocytes develop into hundreds of megakaryocytes. 
Megakaryocytes after getting released from hematopoietic stem cell undergo four 
stages to form platelets. 
 Stage I – Megakaryoblast – 
31 
 
 Stage II – Basophilic megakaryocyte 
 Stage III – Granular megakaryocyte 
 Stage IV – Mature megakaryocyte. 
About 20% of the megakaryoblast produces platelets. In stage II and III, α 
granules and demarcation membranes are formed. The platelet α granules 
contain fibrinogen, Platelet factor – 4 , Von willibrand factor and TGF β. In 
stage IV composition of the platelet membrane occurs. 
 
The Megakaryocyte-platelet hemostatic axis:  
The megakaryocytes are derived from hematopoietic stem cells. These are 
polyploidal cells, an unique feature among all the mammalian cells. This exactly 
means that they can redouble the chromosomal DNA content without undergoing 
full mitotic division. This process is known as endomitosis. Each day about 1000-
2000 platelets are produced from each megakaryocyte. The measurement of 
platelet and megakaryocyte are closely related that they are considered as one 
system - Megakaryocyte platelet haemostatic axis (MKPHA). 
When platelet destruction occurs in the absence of platelet production Mean 
platelet volume alone increases and megakaryocyte ploidy remains 
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unchanged.Megakaryocyte ploidy increases only when the platelet production is 
increased. So the regulation of  ploidy and mean platelet volume are under separate 
hormonal control. 
Physiology of Thrombopoiesis: 
Thrombopoiesis is the generation of platelets from megakaryocytes. Platelet 
formation occurs from the plasma membrane of megakaryocyte. The process of 
platelet formation starts from demarcation membrane. 
 
Demarcation Membrane: 
Demarcation membrane are the extensions of plasma membrane of megakaryocyte  
into the cytoplasm. It divides the cytoplasm as platelet territory. The membranes 
provide substrate for proplatelet process to release platelets. 
Proplatelet Formation: 
The megakaryocytes extends slender process between the cells and the sinusoidal 
lumen. These are the proplatelet processes that contain nascent platelets. 
The major cytokine for platelet formation is thrombopoeitin. The term 
Thrombopoeitin was coined in the year1958, as the primary regulator of platelet 
function.
34
 During the development of  proplatelet into the platelets, 
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thrombopoietin plays a crucial role. In the terminal stage cytokines helps in 
stimulation of the process. Activation of protein kinase Cα is necessary for the 
same process. 
 
Platelet Morphology: 
 The average diameter of platelet is 1.5 – 3 µm. The platelets are surrounded 
by glycocalix, proteins and lipids and contains sialic acid which gives 
negative change to the platelets in electric field. The negative surface charge 
prevents the resting platelets from adhering to each other .Approximately 
50% of platelet lipids are present in plasma membrane. 
 Phosphatidyl serine is negatively charged phospholipid present in plasma 
membrane. Its presence prevents inappropriate coagulation .The discoid 
shape of platelet is due to arrangement of microtubules below the plasma 
membrane.
35,36,37
 
 Lysosomes have numerous enzymes especially the protein in lysosomal 
membrane like LAMP-1, LAMP-2.Lysosomal associated protein acts as 
markers of platelet release reaction.
38,39 
It also contains elastase, collagenase 
which can accelerate the vascular injury at the site of thrombus formation. 
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 Dense bodies have ADP, serotonin, ATP and many other factors. ADP is the 
potent platelet agonist, so its release is an important factor in platelet 
aggregation. Platelets can uptake the oxidized LDL presented by 
macrophages by the release of proteins, thus accelerates atherosclerosis. 
 There are two forms of Platelets 
o Resting form 
o Activated form 
 The platelets may remain in Resting form as long as there is no Agonist 
(Thrombin). The platelets remain resting state due to  
o Negative charge and exposure to Prostacyclin in blood vessel .At the 
same time even a minimal agonist stimulation can activate the 
platelets. 
FUNCTIONS OF PLATELETS: 
 Maintains hemostasis 
 Angiogenesis and promote wound healing 
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Platelet Function: 
 
o Platelet Adhesion: Whenever vascular endothelial injury occurs, 
platelets get adhered to the vessel wall through Von Willibrand  
factor. 
o Platelet Aggregation: The platelets get aggregated by the activation of 
Gp IIb / IIIa receptor. 
o  Secretion: Platelets release growth factor, procoagulants and 
nucleotides and forms clot leading to formation of platelets plug and 
is stabilized by fibrin mesh. 
Clot Retraction: 
Clot retraction is the process by which the clot that is formed after vascular injury 
retracts over time. This process helps the platelet rich thrombi to withstand the 
shear forces in vessel walls. 
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PLATELET INDICES: 
Quantitative index is Platelet count. Qualitative index is Mean platelet volume that 
measures the activity and function of platelets. Others include Platelet distribution 
width, Platelet large cell ratio. Platelet mass is the product of Mean platelet volume 
and platelet count and its inversely proportional to the bleeding time. 
 
MEAN PLATELET VOLUME: 
Mean platelet volume is used to calculate the average size of platelets in the blood. 
It is the indicator of platelet function and activity. The platelets that are newly 
released from bone marrow are the young platelets that are larger, contains more 
proteins (Platelet factor-4).Increase in MPV during increase in platelet production 
or destruction is controlled by release of various cytokines like Interleukin6,3 and 
thrombopoietin. 
 
Normal Mean Platelet Volume:  
The normal mean platelet volume ranges between 7.5fl to 10.5 fl. 
 
37 
 
Conditions with high MPV and low platelet count: 
• Heterozygous thalassemia 
• Iron deficiency anemia 
• Increased platelet turn over 
• Bernald soulier syndrome 
Conditions with high MPV and high Platelet count: 
• Myeloproliferative disorder 
• Inflammation 
• Iron deficiency anemia 
Conditions with normal MPV and high platelet count: 
• Sickle cell anemia 
• CML 
• Inflammation 
• Infections 
Conditions with low MPV:  
• Chronic renal failure 
• Myelosuppresive drugs 
• Marrow hypoplasia 
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• Aplastic anemia 
• Sepsis 
• Big spleen syndrome 
• X linked congenital macrothrombocytopenia 
• Idiopathic Thrombocytopenic Purpura 
 
MPV AND AGE: 
It was an earlier concept that mean platelet volume decreases with age. But the 
recent studies have shown that MPV is determined during thrombopoesis itself by 
its precursor megakaryocyte in the bone marrow.
40,41
 
MPV AND GENDER:   
MPV is likely to be higher in women than in men. It might be due to different 
hormonal profile or it may be due to compensatory mechanism for menstrual blood 
loss in women. Study conducted by Kiewicz and Kemona et al in women of 60 
years of age concluded that there is no significant statistical difference in MPV 
between men and women.
42 
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MPV IN SMOKERS: 
MPV is elevated in elderly with history of smoking. Smoking increases the rate of 
atherosclerosis, thereby increasing the platelet consumption and in turn the new 
platelets formed are larger in size and thus the MPV is elevated.
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MPV IN ALCOHOLICS:  
The significance of mean platelet volume in alcoholics is still controversial but the 
life style modification has been associated with decreased MPV.
44
 
MPV IN ISCHEMIC STROKE: 
Platelets are non-nucleated structure with little or no capacity to synthesize protein. 
The hemostatic function of platelet is established before thrombopoiesis itself by 
megakaryocytes , the precursor of platelets. In certain pathological condition like 
acute ischemic stroke the MPHA axis is altered leading to formation of 
hyperfunctional
45
 platelets that leads to thrombosis causing acute ischemic stroke. 
It is still not clearly concluded that this hyperfunctional platelets are produced 
before or after stroke as a consequence.
45 
 And certain risk factors like Diabetes, 
hypertension leads to some degree of platelet activation preceeding stroke, that 
once the event occurs it gets aggrevated.
45 
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Studies conducted by S.Greisenegger et al a cross sectional study, done at 8 
neurological centres in Austria, Vienna. with 1322 patients. For 846 cases. MPV 
was determined and other 476 cases MPV was not determined. Modified Rankin’s 
Scale was applied in 776 (92%) for whom MPV was done. Multivariate analysis 
performed by binary logistics regression analysis after adjusting for confounding 
factors conclude that MPV in those within the highest quintile had 2.6 times 
unadjusted risk of suffering a severe stroke (95% CI, 1.6 – 4.1; P < 0.001). Same 
MPV and modified Rankinscale compared after 3 months after controlling age and 
sex, MPV was associated with worse outcome. (score 3-6) – odds ratio 2.2, 95% 
CI, 1.1 to 4.5, p = 0.029 . More likely the results suggest increase in MPV 
associated with worst outcome of stroke.
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Philip Bath et al conducted PROGRESS TRIAL. In this 6105 patients were 
included within 5 years of stroke. Selected patients had taken 4-6 weeks of 
peridopil, an antiplatelet drug like Asprin. The study concluded that the difference 
in MPV between the patients on antiplatelets and off the drug is small (≤0.3fl). 400 
strokes were recorded in the follow up period. 301 were ischemic, rest  ICH and 
few were unknown type. Stroke rate was greater in patients with higher MPV (P 
for trend across fifth of MPV = 0.01) and ischemic stroke alone (p=0.01), there 
was no evidence of any difference in patients on single or combination of drug 
therapies.
47
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O Malley et al studied 58 stroke patients in a geriatric population. Platelet variables 
were measured within 48 hours and after 6 months of ischemic stroke and 
compared with controls. MPV was higher in acute stroke (11.3 with 10.1 fl in 
control subjects, p < 0.01, student’s t test). Repeated measurements did not show 
significant changes at 6 months. Platelet change did not relate to outcome
48
. 
There is one way of possibility that MPV have changed even before stroke due to 
some risk factors,and further studies are warranted to analyze this. 
Mayda et al studies 692 patients with ischemic stroke and observed MPV and PC 
were independent risk factors for ischemic stroke (p=.0007 , odds ratio = 0.866, 
95% confidence interval).  Ischemic group MPV (p = 0.013, OR = 1.02). 95% of 
CI associated with worse outcome.
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MPV AND HYPERTENSION: 
In systemic hypertension there is platelet activation and MPV is found to be 
increased. In study conducted by Varole et al in 87 Pre hypertensive patient, 30 
hypertensive patients, the MPV values were significantly higher in both (8.4 ± 0.8 
and 8.8 ± 0.7 Versus 7.9 ± 0.5 fl P < 0.05 and P < 0.001 respectively). 
Hypertensives had increased MPV than Pre hypertensives. Presence of 
Hypertension is an independent parameter in prediction of high MPV.
50 
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MPV AND DIABETES MELLITUS: 
Diabetes is a global pandemic. Platelets function or activation can lead to athero 
thrombosis. The platelets itself can cause vascular injury by three mechanism like 
triggering of arterial thrombosis, microemboli formation in capillaries and 
aggrevation of local progression of vascular disease. 
Platelet activation in DM occurs by 3 ways  
1. The immature young platelets are synthesized in bone marrow. 
2. The metabolic changes in DM , have impact on platelets. They get activated 
with that of metabolic changes. 
3. Vascular damage triggers the activation of platelets in DM. 
Increased MPV directly have positive correlation with that of Glycoprotein GpIIb 
and GpIIb/IIIA receptors on plasma membrane, the Thromboxane synthesizing 
capacity and granule content of platelets. 
The study conducted by Thomas Alex Kodiatte et al in 300 type 2DM and 300 Non 
DM patients, the MPV was higher in Diabetes is (8.29 ± 0.74 fl Versus 7.47 ± 0.73 
fl) (p = 0.001) than non diabetics. 
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MPV showed a significant positive correlation with blood sugar values (both FBS, 
PPBS) and HbA1C. The elevated MPV may be the cause or consequence of 
vascular complication in diabetes
51
. 
MPV IN HYPERLIPIDEMIA:  
Study conducted by Coban et al shared that the baseline MPV was higher in 
dyslipidemic patients (8.4 ± 1.2 fl VS 8.1 ± 0.10 fl P < 0.0005).
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MPV AND METABOLIC SYNDROME: 
MPV is emerging as an atherothrombotic factor. Study conducted by Shah B et al 
as retrospective study in national health and nutrition examination survey found 
that MPV was significantly elevated in abdominal obesity (P = 0.03) and low HDL 
(P = 0.04). The metabolic syndrome was defined by National Cholesterol 
Education Program Adult Treatment Panel III definition.
53
 
MPV AND ANTIPLATELET DRUGS:  
The essential step in hemostasis is platelet aggregation which is involved in many 
pathological process like ischemic stroke, TIA, atherosclerosis. Aspirin irreversibly 
inhibits platelet aggregation by inhibition of cyclooxygenase and TXA2 pathway. 
It is used in secondary prevention of stroke and primarily in TIA. Stephen Erhart 
conducted study on influence of Asprin on platelets. In the studies conducted it 
44 
 
was concluded that Asprin does not influence MPV level before or after the 
stroke.
54
 
MPV AND ISCHEMIC HEART DISEASE: 
Large platelets act as the risk factor in developing coronary occlusion, leading to 
acute coronary syndrome. Studies conducted by M M Khandekar et al in 210 cases 
of acute coronary syndrome, the MPV, PWD , P-LCR were significantly elevated 
in patients with acute myocardial infarction and unstable angina.
55
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METHODOLOGY 
SOURCE OF DATA: 
The study was conducted on patients with Ischemic stroke of first episode for the 
patients admitted in Medical wards in Institute of Internal Medicine at Rajiv 
Gandhi Government General Hospital, Chennai. 
Study Design : Case control study 
Sample Size  : 100 patients  
METHOD OF COLLECTION OF DATA: 
After obtaining consent the patients and controls were subjected to detailed history, 
clinical examination and investigations as per the proforma. 
The following criteria were applied for selection of patients in the study group. 
Inclusion Criteria : 
First episode of Ischemic Stroke (confirmed by 
imaging studies) with or without risk factors.  
Controls   : Normal people 
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Exclusion Criteria : 1. Hemorrhagic stroke, 
    2. Recurrent stroke, 
    3. Patient already on antiplatelet drugs, 
    4. Thrombocytopenia. 
    5. Known case of hereditary disorders of large platelets 
INVESTIGATIONS: 
All the patients and controls underwent the following investigations. 
• Complete hemogram 
• Fasting and post prandial blood sugars 
• Fasting lipid profile 
• Electrocardiogram 
• Echocardiography 
• Imaging studies for patients alone (CT , MRI) 
For the measurement of Mean Platelet Volume 2ml of Blood sample was 
collected from the antecubital vein using 2cc syringe and transferred to an 
EDTA test tube and analyzed in an automated cell counter Sysmex KX21 
Blood samples were taken in patients with ischemic stroke at the time of 
admission, after one week and at the end of 1month. 
47 
 
CRITERIA/CASE DEFINITION FOR CLASSIFYING THE PATIENTS 
AND CONTROLS: 
(1) DIAGNOSIS OF DIABETES MELLITUS: 
(a) Fasting Plasma Glucose > 126mg/dl and 2 Hours post prandial plasma glucose 
> 200mg/dl or HbA1c ≥ 6.5. 
(b) Known cases of type 2 Diabetes Mellitus taking/not taking medications. 
(2) HYPERTENSION: 
(a) Blood Pressure > 140/90 mm of Hg recorded in sitting posture on each of 2 or 
more visits. 
(b) Known hypertensive patients taking/not taking medications 
(3) DYSLIPIDEMIA: 
(a) Total cholesterol ≥200 mg/dl. 
(b) Known cases of dyslipidemia with or without medications. 
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(4) CARDIOVASCULAR DISEASE: 
(a) History of Chest pain, breathlessness on exertion, prior myocardial infarction, 
congestive cardiac failure. 
(b)ECG features 
• Left ventricular hypertrophy. 
• Ischaemic heart disease – ST – T  changes 
• Features of old myocardial infarction. 
(c) Echocardiography (in selected situations only) 
• Regional wall motion abnormalities (RWMA) 
• Decreased Ejection Fraction 
(5) STROKE: 
History, clinical examination and imaging studies (CT/MRI) for stroke was done. 
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OBSERVATIONS AND RESULTS 
 
SAMPLE: 
The study was conducted at the Rajiv Gandhi Government General Hospital 
Chennai. 100 cases who met the inclusion criteria and 50 age and sex matched 
controls were included in the study after obtaining informed consent. 
DATA ANALYSIS: 
The statistical analysis was done using GraphPad Prism version 6.00 for Windows, 
GraphPad Software, La Jolla California USA. MS Excel and Word were used to 
generate tables and graphs. 
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TABLE 1: SEX DISTRIBUTION 
Males constituted 60 % of the cases and controls and the remainder 40 % were 
females. 
SEX 
CASES CONTROLS 
Number Percentage Number Percentage 
Male 60 60 30 60 
Female 40 40 20 40 
Total 100  50  
 
 
 
CONTROLS
Males 60%
Females 40%
CASES
 Males 60%
Females 40%
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TABLE 2: AGE DISTRIBUTION 
The mean age of cases was 53.49 years and mean age of controls was 54.12 years. 
The differences in the mean age of cases and controls was not significant (p value 
> 0.05).Thus cases and controls were matched for their age. 
 
AGE DISTRIBUTION 
(Yrs) 
CASES CONTROLS 
31 – 40 16 8 
41 – 50 28 14 
51 – 60 28 14 
61 – 70 20 10 
71 – 80 8 4 
Mean ± SD 53.49 ± 11.33 54.12 ± 12.09 
Standard Error of mean 1.13 1.71 
P value (Unpaired t test) 0.76 ( Not significant ) 
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TABLE 3: AGE WISE SEX DISTRIBUTION 
The female patients (mean 60.08 years) were significantly older than male patients 
(mean 49.10 years) with a p value < 0.0001. Most of the male patients were in the 
age group of 31 – 50 years whereas majority of female patients were in age group 
of 51 – 70 years. 
AGE DISTRIBUTION 
(yrs) 
MALES FEMALES 
31 – 40 16 0 
41 – 50 23 5 
51 – 60 13 15 
61 – 70 5 15 
71 - 80 3 5 
Mean ± SD 49.10 ± 10.73 60.08 ± 8.83 
Standard Error of Mean 1.40 1.39 
P value ( Unpaired t test ) <0.0001 ( Significant ) 
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TABLE 4: RISK FACTORS IN CASES AND CONTROLS 
a) Hypertension: 
Hypertension is the most common risk factor in both cases and controls occurring 
around 74% and 60% respectively.  
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FACTOR 
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Hypertension 74 74 30 60 
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b) Diabetes Mellitus 
Diabetes Mellitus as a risk factor in cases and control were 47% and 42 % 
respectively. 
RISK 
FACTOR 
CASES ( n = 100 ) CONTROLS ( n = 50 ) 
Number Percentage Number Percentage 
Diabetes 47 47 21 42 
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c) Coronary Artery Disease: 
CAD as a risk factor in cases and control were 32% and 32 % respectively. 
RISK 
FACTOR 
CASES ( n = 100 ) CONTROLS ( n = 50 ) 
Number Percentage Number Percentage 
CAD 32 32 16 32 
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d) Dyslipidemia: 
Dyslipidemia as a risk factor in cases and control were 35% and 40 % respectively. 
RISK 
FACTOR 
CASES ( n = 100 ) CONTROLS ( n = 50 ) 
Number Percentage Number Percentage 
Dyslipidemia 35 35 20 40 
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e) Smoking: 
Smoking is the second common risk factor next to SHT and Smoking as a risk 
factor in cases and control are 48% and 32 % respectively. 
 
 
 
 
0
5
10
15
20
25
30
35
40
45
50
Number
Percentage
Number
PercentageCASES ( n = 100 )
CONTROLS ( n = 50 )
Smoking
Smoking
RISK 
FACTOR 
CASES ( n = 100 ) CONTROLS ( n = 50 ) 
Number Percentage Number Percentage 
Smoking 48 48 16 32 
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f) Alcohol: 
Alcohol as a risk factor in cases and control are 45% and 24 % respectively. 
RISK 
FACTOR 
CASES ( n = 100 ) CONTROLS ( n = 50 ) 
Number Percentage Number Percentage 
Alcohol 45 45 12 24 
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TABLE 5: INFARCT TERRITORY 
The most common patterns were the tempero - parietal and parietal infarcts 
followed by corona radiata infarcts. The MCA territory was predominantly 
involved around 94 %. This was followed by involvement of posterior circulation 
and combined MCA and ACA territory – 3 % each. 
TERRITORY CASES 
MCA 94 
VERTEBRAL / BASILAR ARTERY 3 
MCA + ACA 3 
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TABLE 6: OUTCOME OF THE PATIENTS – MODIFIED RANKIN SCALE 
The clinical outcome of the patients was assessed using modified Rankin Scale. 
The scale is from 0 – 6. A score of 0 implies perfect health with no symptoms, 
whereas a score of 6 implies death. 26% of patients had a score of 2 and 18% had a 
score of 3. 19% had no symptoms. 8% of patients did not survive.   
MODIFIED RANKIN SCALE PERCENTAGE OF PATIENTS 
0 (No symptoms) 19 
1 14 
2 26 
3 18 
4 9 
5 6 
6 (Death) 8 
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TABLE 7: COMPARISON OF PLATELET COUNTS IN CASES AND 
CONTROLS 
The platelet counts were slightly lower in the stroke patients compared to controls 
but this difference was statistically not significant. 
PLATELET COUNT( x 
10
5 
cells/cumm) 
CASES (n=100) CONTROLS (n=50) 
Mean 1.84 1.93 
Standard Deviation 0.27 0.27 
Standard Error of Mean 0.027 0.039 
P value 0.124 
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TABLE 8: COMPARISON OF MEAN PLATELET VOLUME IN CASES 
AND CONTROLS 
The mean platelet volume in stroke patients was significantly higher than controls. 
The p value was less than 0.0001. There was no significant differences in mean 
platelet volumes on day1, day7, day28 implying that platelet volumes tend to be 
elevated for some time after stroke. 
Another implication is that Aspirin does not alter the platelet volume over a short 
duration of 4 weeks. 
MEAN 
PLATELET 
VOLUME(in 
Fl) 
CONTROL 
CASES 
DAY 1 DAY 7 DAY 8 
Mean 9.29 12.28 12.30 12.27 
Standard 
Deviation 
0.59 2.55 2.50 2.57 
Standard Error 
of Mean 
0.08 2.5 2.5 2.5 
Confidence 
Intervals 
9.12-9.46 11.77-12.79 11.77-12.76 11.78-12.81 
65 
 
Comparison of Mean 
Platelet Volume 
P valve (Unpaired T test) Inference 
Controls versus 
Cases(day1) 
< 0.0001 Significant 
Day1 versus Day7 0.98 Not significant 
Day1 versus Day28 0.92 Not significant 
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TABLE 9: COMPARISON OF MEAN PLATELET VOLUME IN MALE 
AND FEMALE 
In our study there were no significant differences in mean platelet volume among 
males and females in both cases and controls. 
MEAN 
PLATELET 
VOLUME 
MALE FEMALE 
CASE CONTROL CASE CONTROL 
Mean 12.27 9.20 12.25 9.42 
Standard 
Deviation 
2.56 0.59 2.54 0.57 
Standard error 
of mean 
0.33 0.10 0.40 0.12 
P value 
Male Controls versus Female Controls - 0.20 (Not significant) 
Male Cases versus Female Cases           - 0.97 (Not significant) 
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TABLE 10: MEAN PLATELET VOLUME AND AGE  
There was no significant alteration in mean platelet volume with ageing. 
MEAN 
PLATELET 
VOLUME 
AGE ≥ 60 YEARS AGE < 60 YEARS 
CASE CONTROL CASE CONTROL 
Mean 12.76 9.36 12.72 9.24 
Standard 
Deviation 
2.42 0.54 2.77 0.62 
Standard error 
of mean 
0.30 0.12 0.48 0.12 
P value 
 Controls  - 0.49 (Not significant) 
 Cases - 0.22 (Not significant) 
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TABLE 11: MEAN PLATELET VOLUME AND HYPERTENSION 
The mean platelet volume was higher among hypertensives, compared to non 
hypertensives and the difference was significant with a p value of 0.02. This 
implies that hypertension increases mean platelet volume thereby increasing the 
risk and severity of stroke. 
RISK FACTOR LEVELS CASES CONTROLS 
HYPERTENSION 
Hypertensives 12.59 9.33 
Non hypertensives 11.33 9.23 
P values 
HT versus Non HT Cases – 
0.02(significant) 
HT versus Non HT Controls – 0.06 
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TABLE 12: MEAN PLATELET VOLUME AND DIABETES MELLITUS 
The mean platelet volume was slightly higher in both cases and controls with 
diabetes mellitus but the difference was not significant. 
RISK FACTOR LEVELS CASES CONTROLS 
DIABETES 
MELLITUS 
Diabetics 12.57 9.39 
Non diabetics 12.02 9.29 
P values 
DM versus Non DM Cases – 0.28 
DM versus Non DM Controls – 0.35 
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TABLE 13: MEAN PLATELET VOLUME AND DYSLIPIDEMIA 
The mean platelet volume was slightly higher in patient with serum cholesterol 
greater than 200 compared to less than 200 but the difference was not statistically 
significant. 
RISK FACTOR LEVELS CASES CONTROLS 
DYSLIPIDEMIA 
Cholesterol>200 12.39 9.54 
Cholesterol<200 12.09 9.12 
P values 
Cases – 0.55 
Controls – 0.11 
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TABLE 14: MEAN PLATELET VOLUME AND SMOKING 
The mean platelet volume is higher in smokers than in non smokers but the 
difference is not significant. 
RISK FACTOR LEVELS CASES CONTROLS 
SMOKING 
Smokers 12.48 9.34 
Non smokers 12.05 9.15 
P values 
Smokers versus Non smokers Cases – 
0.41 
Smokers versus Non smokers Control-
0.32 
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TABLE 15: MEAN PLATELET VOLUME AND ALCOHOL 
Alcoholics had higher mean platelet volume compared to non alcoholics but the 
difference was not significant. 
RISK FACTOR LEVELS CASES CONTROLS 
ALCOHOL 
Alcoholics 12.30 9.42 
Non alcoholics 12.15 9.26 
P value 
Alcoholic versus Non alcoholic cases-
0.77 
Alcoholic versus Non alcoholic control-
0.45 
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TABLE 16: CLINICAL SEVERITY OF STROKE AND MEAN PLATELET 
VOLUME 
The clinical severity of stroke was assessed and graded according to Modified 
Rankin scale with scores varying from 0 having no significant disability to 6 
implying death. The mean of mean platelet volumes of patients in each score from 
0 to 6 was compared. The .patients who had a score of 6 i.e death had significantly 
elevated mean platelet volumes compared to lower scores like 0,1,2. There was no 
significant difference in other scores. 
This implies that patients who have a higher mean platelet volume on day 1 have 
high risk of adverse outcomes including death compared to patients having low 
mean platelet volume. 
MODIFIED RANKIN 
SCALE 
PERCENTAGE OF 
PATIENTS 
MEAN MPV 
0 19 12.91 
1 14 12.61 
2 26 13.21 
3 18 13.57 
4 9 13.81 
5 6 14.35 
6 8 15.86 
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COMPARISON P VALUE (unpaired t test) 
MPV in patients with score 0 versus6 
MPV in patients with score 1 versus 6 
MPV in patients with score 2 versus 6 
Less than 0.05 (significant) 
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TABLE 17: MEAN PLATELET VOLUME AND MODIFIED RANKIN 
SCALE CORRELATION ANALYSIS  
The correlation of mean platelet volume with the Modified Rankin Score was 
calculated using Pearson formula. Though a positive correlation was present, the 
correlation was not significant 
MEAN PLATELET 
VOLUME AND 
MODIFIED RANKIN 
SCALE CORRELATION 
PEARSON FORMULA 
r value 0.1812 
Confidence interval 0.018 – 0.364 
P value 0.07 (Not significant) 
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DISCUSSION 
 
This study is a case control study conducted on 100 patients with first episode of 
acute ischemic stroke and 50 controls. In 100 patients 60 were male and 40 were 
females. Out of 50 controls taken 30 were male, 20 female. The mean age of cases 
studied was 53.49 years when compared to 54.12 years for the controls. The 
maximum number of cases in this study were in the age group between 35-50 
years. The mean age in males was 49.10 years, the mean age in female was 60.08 
years. 
The mean age group in our study was 53.49 years which was much lower 
compared to other studies. There was male preponderance in this study similar to 
all other studies except for O’Malley and Pikija et al that showed female 
preponderance. 
RISK FACTORS FOR STROKE: 
In this study hypertension was found to be most prevalent risk factor with 74% 
among cases and 60% among controls. Study conducted by A.Muscari et al 
showed hypertension is most prevalent risk factor with 84.7%
56
. Study conducted 
by Pikija et al showed hypertension is most common risk factor with 82.7%
57
. 
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The next common risk factor is smoking, diabetes and then comes alcohol and 
dyslipidemia. 
In this study men have higher incidence of ischemic stroke compared to women. 
Study conducted by Petty et al showed that age adjusted incidence of stroke rate is 
in more in men than in women
58
. Wiszniewska m et al conducted a study with risk 
factor distribution and concluded that female sex is associated with poor 
prognosis
59
. 
MPV AND RISK FACTORS: 
In this study average mean platelet volume in hypertensive cases were 12.59 
compared to 9.33 in controls. The mean platelet volume in non hypertensive cases 
was 11.33 compared to 9.33 in controls. The mean platelet volume elevation was 
statistically significant in hypertensives compared to non hypertensives with 
ischemic stroke with significant p value 0.02.This is similar to the study conducted 
by Coban E et al  which showed significant elevation of MPV in hypertensives. 
The association of MPV with diabetes, smoking, alcohol were not statistically 
significant. 
MPV AND GENDER: 
Mean platelet volume in male cases was 12.27 and 12.25 in female cases. There 
were no significant differences between male and female. Many other studies also 
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did not show significant differences of mean platelet volume with gender except 
for the study done by Anna M.Butkiewicz et al which showed MPV was elevated 
in females.  
MEAN PLATELET VOLUME AND ISCHEMIC STROKE 
In this current study, MPV is significantly elevated in ischemic stroke patients 
compared to controls. This is similar to findings of Philips Bath et al in 
PROGRESS trial 
63
. 
Elevation of MPV in the first day is associated with worst outcome. This was 
similar to the study conducted by Greisenegger et al which showed elevated MPV 
is associated with worst outcome. 
In this study the MPV level remained to be constant for about a month, with 
factors like drugs not influencing it. This was similar to the study conducted by 
O’Malley et al  who conducted study in 58 elderly stroke patients and measured 
platelet variables in acute (<48hours) and chronic(>6 months) of ischemic stroke. 
MPV was significantly elevated and platelet count was decreased in acute stroke 
compared with controls. There was no significant difference in MPV value after 6 
months. 
 64
 
 
In this study platelet count is showing slightly lower trend in the cases with an 
average of 1.84±0.27 when compared to controls 1.93±0.27.This is however not 
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statistically significant. This pattern has been seen in all other studies like 
O’’Malley et al, Butter worth et al, Tohji et al. 
MPV AND SEVERITY OF STROKE: 
S. Greisenegger et al conducted a cross sectional study in 8 centers and applied 
modified Rankin scale after 1 week of acute ischemic stroke in 776 patients. It 
showed elevated MPV was associated with worst outcome
65
. In our study, though 
the correlation of MPV with severity of stroke using modified Rankin Scale did not 
show statistical significance, the MPV was significantly higher in patients with a 
score of 6 compared to lower scores like 0, 1 and 2 O’Malley conducted similar 
study with modified Rankin Scale and determined the outcome as independent 
(grade 0 to 2) dependent (grade 3 to 5) and dead (grade 6). In this study also no 
significant correlation between MPV and severity of ischemic stroke is found. 
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LIMITATIONS OF THE STUDY 
1. The study sample size was small. There were only 100 patients and 50 controls 
in the study. 
2. Seriously ill patients admitted in intensive care units were not included in this 
study due to difficulty in getting the consent. This might have lead to selection 
bias. This could have reflected on the correlation of MPV and the stroke severity. 
3. The controls were matched only for age and sex and not for other risk factors 
which would have been ideal. 
4. Long term follow up of the patients was difficult, so the follow up study was 
done for a short duration of 28 days. If the patients were followed up for 6 months 
as done in other studies, the correlation of MPV with modified Rankin Scale would 
be much more ideal. 
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CONCLUSION 
The study had 100 patients and 50 age and sex matched controls. The main 
conclusions drawn from this study are 
1. The mean platelet volume is significantly higher among stroke patients 
compared to controls. 
2. The mean platelet volume tends to remain elevated at least for duration of 4 
weeks after the onset of stroke. 
3. The patients who had a higher mean platelet volume on day 1 compared to 
other patients had a high risk or adverse outcome including death. 
4. Patients with hypertension had higher mean platelet volume compared to 
normotensives. Thus hypertensives had a higher risk of adverse outcomes. 
5. Drugs like aspirin or statins did not alter the mean platelet volume over 
duration of 4 weeks. 
6. There was no significant variation in mean platelet volumes with age, sex, 
diabetes, smoking and alcohol. 
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ANNEXURE 
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“ASSESSMENT OF MEAN PLATELET VOLUME IN ISCHEMIC STROKE 
PATIENTS AND ITS CORRELATION WITH PROGNOSIS AND SEVERITY” 
Name : 
Age/Sex : 
IP No : 
Address :  
 
Phone No.  : 
 
History Drug History 
❏ Smoking ❏ Anti platelet Drug 
❏ Alcoholism ❏ Aspirin 
❏ Diabetes ❏ Chemotherapy  
❏ Systemic hypertension ❏ Other Drugs 
❏ Coronary Artery Disease  
❏ Hyperlipidemia   
 
INVESTIGATIONS: 
RFT 
❏ Glucose  mg/dl 
❏ Urea  mg/dl 
❏ Creatinine  mg/dl 
❏ Na+  mEq/l 
❏ K+  mEq/l 
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D1 D7 D28  
❏ WBC    103/µL 
❏ RBC    106/µL 
❏ Hemoglobin    gm/Dl 
❏ HCT    % 
❏ MCV    fL 
❏ MCH    Pg 
❏ MCHC    gm/dL 
❏ Platelet Count    103/µL 
❏ Lymphocyte %    % 
❏ Mixed % (Basophilis, 
Eosinophils) 
   % 
❏ Neutrophil %    % 
❏ Lymphocyte #    103/µL 
❏ Mixed #    103/µL 
❏ Neutrophil #    103/µL 
❏ Red cell distribution width     fL 
❏ Platelet distribution width    fL 
❏ Mean Platelet volume    fL 
❏ P- LCR (large platelet ratio)    % 
❏ CT Scan Brain     
❏ Area Involved     
❏ Carotid vertebral Dopler      
❏ Modified Rankin’s Score     
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INFORMATION SHEET 
We are conducting a study on “ASSESSMENT OF MEAN PLATELET 
VOLUME IN ISCHEMIC STROKE PATIENTS AND ITS CORRELATION 
WITH PROGNOSIS AND SEVERITY” among patients attending Rajiv 
Gandhi Government General Hospital, Chennai and for that your specimen 
may be valuable to us. 
The purpose of this study is to identify the association between mean 
platelet volume and ischemic stroke. 
We are selecting certain cases and if you are found eligible, we may be 
using your blood samples to do special studies which in any way do not affect 
your final report or management. 
The privacy of the patients in the research will be maintained throughout 
the study. In the event of any publication or presentation resulting from the 
research, no personally identifiable information will be shared. 
Taking part in this study is voluntary. You are free to decide whether to 
participate in this study or to withdraw at any time; your decision will not result 
in any loss of benefits to which you are otherwise entitled. 
The results of the special study may be intimated to you at the end of the 
study period or during the study if anything is found abnormal which may aid 
in the management or treatment. 
 
Signature of Investigator Signature of Participant 
 
Date : 
Place : 
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PATIENT CONSENT FORM 
Study Detail : “ASSESSMENT OF MEAN PLATELET VOLUME IN ISCHEMIC 
STROKE PATIENTS AND ITS CORRELATION WITH PROGNOSIS 
AND SEVERITY” 
Study Centre : Rajiv Gandhi Government General Hospital, Chennai. 
Patient’s Name :  
Patient’s Age :  
Identification Number :  
Patient may check (√) these boxes 
a) I confirm that I have understood the purpose of procedure for the above study. I have 
the opportunity to ask question and all my questions and doubts have been answered to 
my complete satisfaction. 
❏ 
b) I understand that my participation in the study is voluntary and that I am free to 
withdraw at any time without giving reason, without my legal rights being affected. 
❏ 
c) I understand that sponsor of the clinical study, others working on the sponsor’s behalf, 
the ethical committee and the regulatory authorities will not need my permission to 
look at my health records, both in respect of current study and any further research that 
may be conducted in relation to it, even if I withdraw from the study I agree to this 
access. However, I understand that my identity will not be revealed in any information 
released to third parties or published, unless as required under the law. I agree not to 
restrict the use of any data or results that arise from this study. 
❏ 
d) I agree to take part in the above study and to comply with the instructions given during 
the study and faithfully cooperate with the study team and to immediately inform the 
study staff if I suffer from any deterioration in my health or well being or any 
unexpected or unusual symptoms. 
❏ 
e) I hereby consent to participate in this study. ❏ 
f) I hereby give permission to undergo complete clinical examination and hematological 
tests.  
❏ 
 
Signature of Investigator Signature/thumb impression 
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MPV (fl) Drugs 
D
a
y
1
 
D
a
y
7
 
D
a
y
2
8
 
A
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n
 
A
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o
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a
s
 
1 38 M 0 0 N N N 135 1.64 8.9 8.9 8.9 N N 
2 71 F 0 0 Y Y Y 220 1.8 9.8 9.8 9.8 Y Y 
3 74 F 0 0 Y Y Y 225 1.5 10.1 10.1 10.1 Y Y 
4 38 M 0 0 N N N 150 1.95 9.1 9.1 9.1 N N 
5 58 M 20 15 Y N Y 114 1.55 10.3 10.3 10.3 Y Y 
6 75 M 0 0 Y Y Y 190 1.9 8.9 8.9 8.9 Y Y 
7 38 M 5 0 N N N 148 1.76 8.5 8.5 8.5 N N 
8 50 F 0 0 N Y N 132 1.63 10.2 10.2 10.2 N N 
9 60 F 0 0 Y Y Y 225 2.37 9.8 9.8 9.8 Y Y 
10 39 M 0 7 N N N 140 2.2 9.6 9.6 9.6 N N 
11 73 M 0 0 Y Y Y 176 2 9.1 9.1 9.1 Y Y 
12 45 M 13 11 Y N Y 290 2.25 9.8 9.8 9.8 Y Y 
13 67 M 25 25 Y N N 196 1.89 8.7 8.7 8.7 N N 
14 63 F 0 0 N Y Y 180 1.74 8.9 8.9 8.9 Y Y 
15 55 F 0 0 N N Y 193 1.78 9.2 9.2 9.2 Y Y 
16 68 F 0 0 Y Y Y 256 2.2 9.4 9.4 9.4 Y Y 
17 71 F 0 0 Y Y Y 229 1.97 9.1 9.1 9.1 Y Y 
18 46 M 0 6 Y N N 254 1.82 10.5 10.5 10.5 N Y 
19 65 F 0 0 Y Y Y 284 1.89 9.8 9.8 9.8 Y Y 
20 37 M 8 0 Y N N 200 2.25 9.8 9.8 9.8 N N 
21 70 F 0 0 Y Y Y 256 1.67 8.3 8.3 8.3 Y Y 
22 65 F 0 0 N Y Y 228 1.73 9.5 9.5 9.5 Y Y 
23 60 F 0 0 N Y Y 234 1.9 10.6 10.6 10.6 Y Y 
24 50 M 12 0 Y N N 180 1.6 8.1 8.1 8.1 N N 
25 44 F 0 0 N N N 175 1.93 9.1 9.1 9.1 N N 
26 61 F 0 0 Y N N 223 2.1 9.4 9.4 9.4 N Y 
27 42 F 0 0 N N N 143 1.73 9.5 9.5 9.5 N N 
28 38 M 5 0 Y N N 175 2.1 10.1 10.1 10.1 N N 
29 55 F 0 0 N N N 143 2.2 8.7 8.7 8.7 N N 
30 37 M 10 4 Y N N 140 2 8.5 8.6 8.5 N N 
31 51 F 0 0 N N N 133 1.9 8.9 8.9 8.9 N N 
32 39 M 0 0 N N N 195 2.45 8.6 8.6 8.6 N N 
33 41 M 6 7 Y Y N 220 1.45 9.7 9.7 9.7 N Y 
34 58 F 0 0 N N Y 241 2.11 9.6 9.6 9.6 Y Y 
35 63 F 0 0 Y N N 212 2.2 9.1 9.1 9.1 N Y 
36 64 M 20 0 N Y Y 242 2.1 9.3 9.3 9.3 Y Y 
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37 45 F 0 0 N Y N 230 1.73 8.9 8.9 8.9 N Y 
38 36 M 0 2 N N N 177 2.23 9.2 9.2 9.2 N N 
39 74 M 40 38 Y Y Y 198 2.25 10 10 10 Y Y 
40 48 F 0 0 N N N 164 1.8 9.6 9.6 9.6 N N 
41 35 M 3 0 Y N N 135 2.2 8.3 8.3 8.3 N N 
42 40 M 5 4 Y N N 134 1.87 9.4 9.4 9.4 N N 
43 52 M 22 20 Y Y N 170 1.8 8.5 8.5 8.5 N N 
44 60 M 0 0 Y N Y 210 2.3 9.6 9.6 9.6 Y Y 
45 72 F 0 0 Y Y Y 210 2.16 9.4 9.4 9.4 Y Y 
46 52 F 0 0 Y Y N 156 1.55 9 9 9 N N 
47 56 F 0 0 Y N N 173 1.67 9.7 9.7 9.7 N N 
48 65 F 0 0 Y N N 170 2.65 9 9 9 N N 
49 61 F 0 0 Y Y Y 234 1.56 8.8 8.8 8.8 Y Y 
50 43 F 0 0 N N N 118 1.71 8.8 8.8 8.8 N N 
 
 
